8-K: BioVie Inc. Announces 1-for-10 Reverse Stock Split Following Shareholder Approval

BioVie Inc. will implement a 1-for-10 reverse stock split of its common stock, effective August 6, 2024, following shareholder approval at a special meeting.

Summary

• BioVie Inc. held a special meeting of stockholders on July 29, 2024, where a reverse stock split was approved.
• The board of directors approved a 1-for-10 reverse stock split of the company's Class A common stock.
• The reverse stock split will be effective on August 6, 2024, at 12:01 am Eastern Time.
• Every ten shares of common stock will be reclassified into one share.
• The reverse stock split will proportionally reduce the number of shares issuable upon the exercise or vesting of stock options, restricted stock units, and warrants, and increase their exercise prices.
• No fractional shares will be issued; instead, shareholders will receive one full share in lieu of any fractional entitlement.
• Trading of the company's common stock will continue on The Nasdaq Capital Market on a split-adjusted basis starting August 6, 2024.
• The new CUSIP number for the company's common stock following the reverse stock split is 09074F405.

Sentiment

Score: 5

Explanation: The document describes a routine corporate action (reverse stock split) that is neither inherently positive nor negative. The sentiment is neutral.

Positives

• The reverse stock split was approved by shareholders, indicating support for the company's strategic direction.
• The company has taken steps to ensure a smooth transition for shareholders, including providing information through an exchange agent.

Negatives

• The reverse stock split will reduce the number of shares outstanding, which may be perceived negatively by some investors.
• The reverse stock split will proportionally reduce the number of shares issuable upon the exercise or vesting of stock options, restricted stock units, and warrants, and increase their exercise prices.

Risks

• Reverse stock splits can sometimes be viewed negatively by the market and may not achieve the desired effect of increasing the share price.
• The company's stock price may be volatile following the reverse stock split.

Future Outlook

The company will continue trading on The Nasdaq Capital Market on a reverse stock split-adjusted basis starting August 6, 2024.

Industry Context

Reverse stock splits are a common corporate action for companies seeking to increase their stock price or meet listing requirements. This action is not uncommon in the biotech industry.

Comparison to Industry Standards

• Reverse stock splits are a relatively common practice among companies listed on the Nasdaq, particularly those with low share prices.
• Other biotech companies such as Cassava Sciences and Ocugen have also undertaken reverse stock splits in the past to maintain listing compliance or improve their stock price.
• The 1-for-10 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-20 or more.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain the same immediately after the split.
• Holders of stock options, restricted stock units, and warrants will see adjustments to the number of shares and exercise prices.

Next Steps

• The company will begin trading on a split-adjusted basis on August 6, 2024.
• West Coast Stock Transfer, Inc. will correspond with stockholders of record regarding the reverse stock split.

Key Dates

Keywords

reverse stock split, common stock, shareholders, stock options, warrants, Nasdaq, BIVI, corporate action